Alex has a proven track record in identifying, investing and growing business within the pharmaceutical sector. He began his career as a scientist, working in research and for a NYSE quoted drug development company, before moving into early stage pharmaceutical and healthcare investments. He has fulfilled board level investment and operational management roles. He is Chief Scientific Officer at 4d pharma plc.
From 2008, he was a director and shareholder in Aquarius Equity Partners Limited. Aquarius Equity Partners Limited invested in C4XD in 2008, when Alex joined the board as a non-executive director. Prior to joining Aquarius Equity Partners Limited, Alex worked for IP Group plc where he specialised in life science investments, identifying, developing and advising a number of companies in its portfolio, some of which went on to list on AIM.
Alex has been involved in a number of private and public companies, including Nanoco Group plc, admitted to AIM in 2009; Retroscreen Virology Group plc admitted to AIM in 2012; Tissue Regenix Group plc admitted to AIM in 2010; Auralis Limited, which, after investment through Aquarius Equity Partners Limited, delivered a 7 fold return through to its trade sale to ViroPharma Inc in 2010; 4d pharma plc, admitted to AIM in 2014.